Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine

Gomila, Isabel; Barceló, Bernardino; Rosell, A.; Avella, Sonia; Sahuquillo, Laura; Dastis, Macarena

doi:10.1093/jat/bkx047

Cited by 13 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the Alere Triage® TOX Drug Screen assay yielded a F/P for cannabinoids. False-positive results in this assay were obtained provided the drug concentration was greater than 1,000 μg/mL [61].…”

Section: Pantoprazolementioning

confidence: 95%

See 1 more Smart Citation

Guilty or not guilty? — False positive results of common medicines in drug tests: review and practical guide

2023

Folia Medica Cracoviensia

View full text Add to dashboard Cite

Drug-abuse detection tests are becoming increasingly commonplace in patient care today and provide a rapid and effective method for identifying illicit substances. Occasionally, they may yield a positive result, indicating the presence of a substance, even though the individual has not consumed the suspected drug what sometimes can significantly impact both medical and legal decisions. The study outlines the substances that can lead to false-positive drug test results for amphetamines, cannabinoids, and benzodiazepines. The study's findings have revealed pivotal insights for patients receiving chronic treatment and their primary care physicians. Notably, amphetamine assays appear to be most prone to cross-reactivity with other substances. The beta-blocker group of medications, confirmed by various studies to interfere with amphetamine assays, could pose a substantial challenge in drug screening given its widespread use. Efavirenz also warrants mention, as it frequently triggers positive results for both benzodiazepine and cannabinoid assays among its users. This research helps highlight new areas for further investigation and aims to guide clinicians in their daily practice, especially when interpreting questionable positive drug-abuse test results. This comprehensive review serves as a valuable resource for clinicians to navigate false-positive scenarios effectively and maintain the highest standard of patient care.

show abstract

Section: Pantoprazolementioning

confidence: 95%

“…Research reports suggest that the PPI drug pantoprazole may cause a F/P urine immunochemical screening test for THC, a study was conducted to test the claim [61]. In phase 1 of the study, 3 healthy volunteers took 40 mg of pantoprazole once a day, for 5 days.…”

Section: Pantoprazolementioning

confidence: 99%

Guilty or not guilty? — False positive results of common medicines in drug tests: review and practical guide

2023

Folia Medica Cracoviensia

View full text Add to dashboard Cite

show abstract

“…Other IV agents that may be helpful include promethazine (antiemetic) diphenhydramine * (antihistamine) and proton pump inhibitors (Bhandari & Venkatesan, 2016; Calhoun & Pruitt, 2014; Mooers, Srivastava, Garacci, & Venkatesan, 2021). Clinicians assessing for cannabis use in CVS patients (in attempts to differentiate CHS) should note that proton pump inhibitors (IV pantoprazole * in particular) may result in a false-positive cannabis toxicology screen during the ED or inpatient workup (Felton, Zitomersky, Manzi, & Lightdale, 2015; Gomila et al, 2017).…”

Section: Cvs Adult-onsetmentioning

confidence: 99%

Cyclic Vomiting Syndrome and Cannabis Hyperemesis Syndrome

Lathrop

Rosen

Heitkemper

et al. 2023

Gastroenterology Nursing

View full text Add to dashboard Cite

This article provides a narrative review of the state of the science for both cyclic vomiting syndrome and cannabis hyperemesis syndrome along with a discussion of the relationship between these 2 conditions. The scope of this review includes the historical context of these conditions as well as the prevalence, diagnostic criteria, pathogenesis, and treatment strategies for both conditions. A synopsis of the endocannabinoid system provides a basis for the hypothesis that a lack of cannabidiol in modern high-potency Δ9-tetrahydrocannabinol cannabis may be contributory to cannabis hyperemesis syndrome and possibly other cannabis use disorders. In concluding assessment, though the publications addressing both adult cyclic vomiting syndrome and cannabis hyperemesis syndrome are steadily increasing overall, the state of the science supporting the treatments, prognosis, etiology, and confounding factors (including cannabis use) is of moderate quality. Much of the literature portrays these conditions separately and as such sometimes fails to account for the confounding of adult cyclic vomiting syndrome with cannabis hyperemesis syndrome. The diagnostic and therapeutic approaches are, at present, based generally on case series publications and expert opinion, with a very limited number of randomized controlled trials and a complete absence of Level 1 evidence within the cyclic vomiting literature overall as well as for cannabis hyperemesis syndrome specifically.

show abstract

“…Analysis of illicit drugs in urine were performed following the same protocol of meconium analysis [32][33][34]. The analysis of illicit drugs in hair was performed by GC-MS following previously published methods [32,35,36].…”

Section: Urine and Hair Toxicology Testing For Analysis Of Illicit Drugsmentioning

confidence: 99%

Role of Neonatal Biomarkers of Exposure to Psychoactive Substances to Identify Maternal Socio-Demographic Determinants

Jarque

Roca

Gomila

et al. 2021

Biology

Self Cite

View full text Add to dashboard Cite

Background: The accurate assessment of fetal exposure to psychoactive substances provides the basis for appropriate clinical care of neonates. The objective of this study was to identify maternal socio-demographic profiles and risk factors for prenatal exposure to drugs of abuse by measuring biomarkers in neonatal matrices. Methods: A prospective, observational cohort study was completed. Biomarkers of fetal exposure were measured in meconium samples. The mothers were interviewed using a questionnaire. Univariate and multivariate logistic regression analyses were performed. Results: A total of 372 mothers were included, 49 (13.2%) testing positive for psychoactive substances use: 24 (49.0%) for cannabis, 11 (22.5%) for ethyl glucuronide, six (12.2%) for cocaine, and in eight (16.3%) more than one psychoactive substance. Mothers who consumed any psychoactive substance (29.7 ± 6.6 years) or cannabis (27.0 ± 5.7 years) were younger than non-users (32.8 ± 6.2 years, p < 0.05). Cocaine (50.0% vs. 96.9%, p < 0.05) and polydrug users (37.5% vs. 96.9%, p < 0.05) showed a lower levels of pregnancy care. Previous abortions were associated with the use of two or more psychoactive substances (87.5% vs. 37.8%, p < 0.05). Single-mother families (14.3% vs. 2.5%, p < 0.05) and mothers with primary level education (75.5% vs. 55.1%, p < 0.05) presented a higher consumption of psychoactive substances. Independent risk factors that are associated with prenatal exposure include: maternal age < 24 years (odds ratio: 2.56; 95% CI: 1.12–5.87), lack of pregnancy care (odds ratio: 7.27; 95%CI: 2.51–21.02), single-mother families (odds ratio: 4.98; 95%CI: 1.37–8.13), and active tobacco smoking (odds ratio: 8.13; 95%CI: 4.03–16.43). Conclusions: These results will allow us to develop several risk-based drug screening approaches to improve the early detection of exposed neonates.

show abstract

Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine

Cited by 13 publications

References 13 publications

Guilty or not guilty? — False positive results of common medicines in drug tests: review and practical guide

Guilty or not guilty? — False positive results of common medicines in drug tests: review and practical guide

Cyclic Vomiting Syndrome and Cannabis Hyperemesis Syndrome

Role of Neonatal Biomarkers of Exposure to Psychoactive Substances to Identify Maternal Socio-Demographic Determinants

Contact Info

Product

Resources

About